Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 18Small Cell Lung Carcinoma 3Radiation Pneumonitis 2Mesothelioma, Malignant 2Lung Neoplasms 2Recurrence 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × nintedanib × Thoracic × Clear all
NCT07485920 2026-03-20

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

The Affiliated Hospital of Qingdao University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01441297 2017-08-25

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
24 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02152059 2016-07-06

A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

AHS Cancer Control Alberta

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡